Mizco enters distribution agreement with Curve Distribution Services
AVENEL, N.J. Mizco International has inked an exclusive deal with Curve Distribution Services to sell its iEssentials and Cellular Innovations mobile technology accessory products in Canada.
“For most of the last 20 years, we have focused our efforts on building out our core United States customer base,” said Sam Mizrahi, Mizco EVP. “And, while we certainly have new goals and objectives to realize here in our home market, it is time that we take the next step forward in our North American marketing plan. This agreement with Curve Distribution Services will help us to significantly and quickly penetrate the entire Canadian market with our iEssentials and Cellular Innovations product lines. With this agreement, Canadian retailers will now be able to offer their customers a combined product line that exceeds more than 1,000 individual SKUs.”
Headquartered in Calgary, Alberta, Curve Distribution Services is a full-service sales strategy, distribution and logistics planning and support company. “With this agreement, Canadian consumers will now be able to purchase an entirely new range of mobile technology accessories that break new ground in price and performance value,” Curve Distribution Services sales director Bob Duszynski said.
Genentech amends approval application for expanded use of Avastin
SOUTH SAN FRANCISCO, Calif. Biotech company Genentech has amended its application to the Food and Drug Administration seeking an additional approval for one of its drugs, which the FDA has deemed a “major amendment,” Genentech said Monday.
Genentech, part of Swiss drug maker Roche, is seeking approval for Avastin (bevacizumab) combined with paclitaxel chemotherapy for untreated advanced breast cancer without the HER2 protein. The FDA has granted accelerated approval to Genentech’s application, and the company expects the agency to take action by Dec. 17. The expected action date is based on the FDA’s decision to extend its review period in light of the amendment.
“We are pleased by the FDA’s decision to review additional information on Avastin and are committed to working with the agency during this extended review period,” Genentech EVP product development and chief medical officer Hal Barron said.
Avastin already is approved for treating cancers of the colon and rectum, lungs and kidneys.
Kroger commences Giving Hope a Hand campaign for breast cancer
CINCINNATI Kroger’s family of stores will showcase breast cancer survivors in its annual Giving Hope a Hand campaign to support breast cancer initiatives in communities across the country.
This year, 56 women share their stories of survival on marketing materials and custom packages of national and Kroger brand items, which will be sold exclusively in Kroger’s family of stores. Kroger’s campaign includes a storewide sales promotion of popular items, many of which will feature exclusive, specially marked pink packaging. This year, 1,800 items, including Kroger’s own products and popular items from such Kroger partners as Pepsi, Kellogg, Kraft, General Mills, Procter & Gamble and Kimberly Clark will be marked with special pink shelf tags to highlight their participation.
“All of us at Kroger applaud these terrific associates for choosing to share their personal stories of fighting breast cancer with our customers and associates,” said David Dillon, Kroger’s chairman and CEO. “We are pleased to have our great people featured in our annual campaign, as they inspire others to take care of themselves and each other.”